CN102008478A - 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 - Google Patents
装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 Download PDFInfo
- Publication number
- CN102008478A CN102008478A CN2010102134271A CN201010213427A CN102008478A CN 102008478 A CN102008478 A CN 102008478A CN 2010102134271 A CN2010102134271 A CN 2010102134271A CN 201010213427 A CN201010213427 A CN 201010213427A CN 102008478 A CN102008478 A CN 102008478A
- Authority
- CN
- China
- Prior art keywords
- capsule
- tablet
- cefalexin
- tablets
- ambroxol hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 69
- 229940106164 cephalexin Drugs 0.000 title claims abstract description 47
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 title claims abstract description 47
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960000985 ambroxol hydrochloride Drugs 0.000 title claims abstract description 31
- 239000003086 colorant Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 abstract description 16
- 239000000047 product Substances 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000006227 byproduct Substances 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 2
- 239000007902 hard capsule Substances 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 229960005174 ambroxol Drugs 0.000 description 14
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 14
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 9
- NVIAYEIXYQCDAN-CLZZGJSISA-N 7beta-aminodeacetoxycephalosporanic acid Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](N)[C@@H]12 NVIAYEIXYQCDAN-CLZZGJSISA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 229930182470 glycoside Natural products 0.000 description 9
- 150000002338 glycosides Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- -1 amino 3.5-dibromo-benzyl Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
实施例1 | ||
0天含量 | 氨溴索(%) | 99.83 |
头孢氨苄(%) | 99.77 | |
0天有关物质 | N-A873CL | 0.02 |
N AB773XX | 0.01 |
7-氨基去乙酰氧基头孢烷酸 | 0.1 | |
α-苯苷氨酸 | 0.1 | |
5天含量 | 氨溴索(%) | 99.57 |
头孢氨苄(%) | 99.49 | |
5天有关物质 | N A873CL | 0.03 |
N AB773XX | 0.02 | |
7-氨基去乙酰氧基头孢烷酸 | 0.3 | |
α-苯苷氨酸 | 0.3 | |
10天含量 | 氨溴索(%) | 99.88 |
头孢氨苄(%) | 99.36 | |
10天有关物质 | N A873CL | 0.03 |
N-AB773XX | 0.05 | |
7-氨基去乙酰氧基头孢烷酸α-苯苷氨酸 | 0.50.3 |
实施例1 | ||
0天含量 | 氨溴索(%) | 99.83 |
头孢氨苄(%) | 99.77 | |
0天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.01 | |
7-氨基去乙酰氧基头孢烷酸 | 0.1 |
α-苯苷氨酸 | 0.1 | |
5天含量 | 氨溴索(%) | 99.51 |
头孢氨苄(%) | 99.42 | |
5天有关物质 | N-A873CL | 0.04 |
N-AB773XX | 0.01 | |
7-氨基去乙酰氧基头孢烷酸 | 0.2 | |
α-苯苷氨酸 | 0.3 | |
10天含量 | 氨溴索(%) | 99.38 |
头孢氨苄(%) | 99.66 | |
10天有关物质 | N A873CL | 0.03 |
N AB773XX | 0.04 | |
7-氨基去乙酰氧基头孢烷酸α-苯苷氨酸 | 0.40.2 |
实施例1 | ||
0天含量 | 氨溴索(%) | 99.83 |
头孢氨苄(%) | 99.77 | |
0天有关物质 | N-A873CL | 0.02 |
N-AB773XX | 0.01 | |
7-氨基去乙酰氧基头孢烷酸 | 0.1 | |
α-苯苷氨酸 | 0.1 |
5天含量 | 氨溴索(%) | 99.54 |
头孢氨苄(%) | 99.39 | |
5天有关物质 | N-A873CL | 0.03 |
N-AB773XX | 0.02 | |
7-氨基去乙酰氧基头孢烷酸 | 0.3 | |
α-苯苷氨酸 | 0.4 | |
10天含量 | 氨溴索(%) | 99.58 |
头孢氨苄(%) | 99.76 | |
10天有关物质 | N A873CL | 0.03 |
N AB773XX | 0.04 | |
7-氨基去乙酰氧基头孢烷酸α-苯苷氨酸 | 0.20.3 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102134271A CN102008478A (zh) | 2010-06-30 | 2010-06-30 | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102134271A CN102008478A (zh) | 2010-06-30 | 2010-06-30 | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102008478A true CN102008478A (zh) | 2011-04-13 |
Family
ID=43838949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102134271A Pending CN102008478A (zh) | 2010-06-30 | 2010-06-30 | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102008478A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104606166A (zh) * | 2015-02-04 | 2015-05-13 | 上海华源安徽仁济制药有限公司 | 一种复方头孢氨苄胶囊及其制备方法 |
-
2010
- 2010-06-30 CN CN2010102134271A patent/CN102008478A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104606166A (zh) * | 2015-02-04 | 2015-05-13 | 上海华源安徽仁济制药有限公司 | 一种复方头孢氨苄胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pogue et al. | Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing | |
Bockbrader et al. | A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin | |
US20180055770A1 (en) | Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies | |
BRPI0620865A2 (pt) | métodos para melhorar a farmacocinética de inibidores das integrases do hiv | |
Sandercock et al. | A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial | |
Atkinson et al. | A pharmacokinetic analysis of a novel fixed dose oral combination of paracetamol and ibuprofen, with emphasis on food effect | |
CN201701513U (zh) | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 | |
CN104394691A (zh) | 用5-氨基水杨酸治疗过敏性肠道综合症的组合物和方法 | |
CN102008478A (zh) | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 | |
CN201701511U (zh) | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 | |
Vuono et al. | Skin rash during treatment with generic itraconazole | |
CN102008467A (zh) | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 | |
CN102018694A (zh) | 装有硫酸沙丁胺醇片和盐酸氨溴索片的片剂胶囊 | |
CN201701512U (zh) | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 | |
CN201701514U (zh) | 装有罗红霉素片和盐酸氨溴索片的片剂胶囊 | |
CN201701510U (zh) | 装有硫酸沙丁胺醇片和盐酸氨溴索片的片剂胶囊 | |
Shanmugam et al. | Formulation and evaluation of sustained release matrix tablet of Zidovudine using different polymers | |
CA3181629A1 (en) | Rabeximod in the treatment of rheumatoid arthritis | |
CN103860532B (zh) | 美金刚和二甲双胍的复方药用组合物及其制备方法 | |
CN102018709A (zh) | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 | |
CN106038522A (zh) | 大黄酸在制备抗抑郁症药物中的用途 | |
CN202168960U (zh) | 含有奥美沙坦酯、氨氯地平和氢氯噻嗪的复方制剂 | |
CN202010289U (zh) | 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 | |
CN102018719A (zh) | 装有罗红霉素片和盐酸氨溴索片的片剂胶囊 | |
CN202146449U (zh) | 装有洛匹那韦片和利托那韦片剂胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG FUHE HUAXING PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: WU GUANGYAN Effective date: 20110519 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 151100 HEILONGJIANG FUHE HUAXING PHARMACEUTICAL GROUP CO., LTD., NO. 34, TAIPING ROAD, ZHAODONG CITY, HEILONGJIANG, SUIHUA CITY, HEILONGJIANG PROVINCE TO: 151100 HEILONGJIANG FUHE HUAXING PHARMACEUTICAL GROUP CO., LTD., NO. 34, TAIPING ROAD, ZHAODONG CITY, HEILONGJIANG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110519 Address after: 151100 Heilongjiang Zhaodong Taiping Road 34, Heilongjiang Dilong pharmaceutical Limited by Share Ltd Applicant after: Heilongjiang Fuhe Huaxing Pharmaceutical Group Co., Ltd. Address before: Taiping Road Heilongjiang 151100 Zhaodong city of Heilongjiang province Suihua City, No. 34 Heilongjiang Dilong pharmaceutical Limited by Share Ltd Applicant before: Wu Guangyan |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110413 |